89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

NCT04757090 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Insufficient staff

Conditions

HER2-positive Solid Tumor
HER-2 Positive Cancer

Interventions

DRUG: 89Zr-trastuzumab

Sponsor

Washington University School of Medicine

Collaborators

[object Object]